ION 717
Alternative Names: ION-717Latest Information Update: 30 Aug 2024
At a glance
- Originator Ionis Pharmaceuticals
- Class Antisense oligonucleotides
- Mechanism of Action Gene silencing; Prion protein expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Prion diseases
Most Recent Events
- 04 Jan 2024 Phase-I/II clinical trials in Prion diseases in Australia, Japan, Israel, Italy (Intrathecal) (NCT06153966)
- 04 Jan 2024 Phase-I/II clinical trials in Prion diseases in Canada, Germany, Spain (Intrathecal) (NCT06153966)
- 01 Dec 2023 Phase-I/II clinical trials in Prion diseases in USA (Intrathecal) (NCT06153966)